The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $860,330 in first-year total cost, median $430,165.
Most frequent study sections
- Neurological Sciences and Disorders A Study Section[NSD-A]1
- Neurological Sciences and Disorders B Study Section[NSD-B]1
Most frequent institutions
- DIGNIFY THERAPEUTICS, LLC1
- SHIFT PHARMACEUTICALS HOLDINGS, INC.1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding1U44NS129628-01 | BURGARD, EDWARD | DIGNIFY THERAPEUTICS, LLC, NC | $499,393 | NSD |
| 2023 | IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.1U44NS127351-01A1 | OCONNOR, STEVE | SHIFT PHARMACEUTICALS HOLDINGS, INC., MO | $360,937 | NSD |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.